HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bates, D. Search for Related Content PubMed PubMed Citation Articles by Bates, D.

Subcutaneous sumatriptan during the migraine aura

Department of Neurology (Dr. Bates), Royal Victoria Infirmary, Newcastle-upon-Tyne, UK; Glaxo Research and Development Limited (Dr. Pilgrim, Ms. Ashford, Mr. Dawson, and Ms. Shevlin), Greenford, UK; Zentrum Anaesthesiologie, Rettungs-und Intensivmedizin (Dr. Ensink), Georg-August-Universität, Göttingen, Germany; the Department of Neurology (Dr. Gilhus), University Hospital, Bergen, Norway; and the Department of Neurology (Dr. Olesen), Glostrup Hospital, Copenhagen, Denmark.

This double-blind, placebo-controlled, multicenter, parallel-group study assessed whether subcutaneous sumatriptan administered during the migraine aura would prolong or modify the aura and prevent or delay development of the headache. One hundred seventy-one patients (88 receiving 6 mg sumatriptan, 83 receiving placebo) treated a single attack of migraine with typical aura at home, by self-injection. The median duration of aura following the first injection was 25 minutes for the sumatriptan group and 30 minutes for the placebo group (NS). The aura symptom profile was similar for the two treatment groups. The proportion of patients who developed a moderate or severe headache within 6 hours after dose administration was similar in the two groups –68% among those receiving sumatriptan and 75% among those receiving placebo (NS). Sumatriptan given during the aura did not prolong or alter the nature of the migraine aura and did not prevent or significantly delay headache development.

Address correspondence to Dr. David Bates, Department of Neurology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle-upon-Tyne NE1 4LP, UK. Address reprint requests to Mr. Raymond Dawson, Glaxo Research and Development Limited, Greenford Road, Greenford, Middlesex UB6 OHE, UK.

^*See the Appendix on page 1591 for a complete listing of the publication committee members and the principal investigators.

Received March 14, 1994. Accepted in final form June 2, 1994.

This article has been cited by other articles:

				E. Loder Prophylaxis of menstrual migraine with triptans: Problems and possibilities Neurology, December 10, 2002; 59(11): 1677 - 1681. [Abstract] [Full Text] [PDF]